Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > November 2011 - Volume 19 - Issue 6 > Retrospective Study of Prolonged Versus Intermittent Infusio...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31822e9bf5
Original Articles

Retrospective Study of Prolonged Versus Intermittent Infusion Piperacillin-Tazobactam and Meropenem in Intensive Care Unit Patients at an Academic Medical Center

Dow, Rebekka J. PharmD*; Rose, Warren E. PharmD†; Fox, Barry C. MD‡; Thorpe, Joshua M. PhD, MPH§; Fish, Jeffrey T. PharmD∥

Collapse Box

Abstract

Background: Prolonged infusions of β-lactams are increasingly being utilized because of increased antimicrobial resistance and a lack of new antibiotics in the pipeline.

Methods: A retrospective, observational study evaluated adult patients who received at least 72 hours of piperacillin-tazobactam or meropenem in a medical and surgical intensive care unit (ICU) at an academic medical center. In the first 6 months of the study, all patients received conventional intermittent dosing; in the second 6 months, all patients received these antibiotics by prolonged infusions. The main outcome comparisons between groups were duration of ventilator support, duration of ICU and hospital length of stay, and in-hospital mortality.

Results: A total of 121 patients were included: 54 patients in the intermittent (67% piperacillin-tazobactam, 33% meropenem) and 67 patients in the prolonged group (81% piperacillin-tazobactam, 19% meropenem). The prolonged group demonstrated a significant decrease in ventilator days (−7.2 days; 95% confidence interval [CI], −12.4 to −2.4), ICU length of stay (−4.5 days; 95% CI, −8.3 to −1.4), and hospital length of stay (−8.5 days; 95% CI, −18.7 to −1.2) compared with the intermittent group. The risk of in-hospital mortality was 12.4% in the prolonged infusion group and 20.7% in the intermittent infusion group corresponding to an odds ratio of 0.54 (0.18-1.66).

Conclusions: The results of this study show that the use of prolonged infusions of piperacillin-tazobactam and meropenem could potentially improve clinical outcomes in critically ill populations. As antibiotic resistance continues to increase in gram-negative pathogens, these β-lactam dosing strategies will be important for appropriate treatment.

© 2011 Lippincott Williams & Wilkins, Inc.

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.